BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 10214856)

  • 21. Lack of effect of 2-chlorodeoxyadenosine therapy in patients with chronic lymphocytic leukemia refractory to fludarabine therapy.
    O'Brien S; Kantarjian H; Estey E; Koller C; Robertson B; Beran M; Andreeff M; Pierce S; Keating M
    N Engl J Med; 1994 Feb; 330(5):319-22. PubMed ID: 7904047
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 2-chlorodeoxyadenosine (cladribine) in the treatment of hairy cell leukemia and hairy cell leukemia variant: 7-year experience in Poland.
    Robak T; Błasińska-Morawiec M; Błoński J; Hellmann A; Hałaburda K; Konopka L; Kotlarek-Haus S; Potoczek S; Hansz J; Dmoszyńska A; Urasiński I; Zdziarska B; Dwilewicz-Trojaczek J; Hołowiecki J; Skotnicki AB
    Eur J Haematol; 1999 Jan; 62(1):49-56. PubMed ID: 9918312
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro sensitivity of chronic lymphocytic leukemia B-cells to fludarabine, 2-chlorodeoxyadenosine and chlorambucil: correlation with clinico-hematological and immunophenotypic features.
    Morabito F; Stelitano C; Callea I; Filangeri M; Oliva B; Sculli G; Callea V; Nobile F; Brugiatelli M
    Haematologica; 1996; 81(3):224-31. PubMed ID: 8767527
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of fludarabine, cyclophosphamide/doxorubicin/prednisone, and cyclophosphamide/doxorubicin/vincristine/prednisone in advanced forms of chronic lymphocytic leukemia: preliminary results of a controlled clinical trial. The French Cooperative Group on Chronic Lymphocytic Leukemia.
    Semin Oncol; 1993 Oct; 20(5 Suppl 7):21-3. PubMed ID: 8235691
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Response to fludarabine in B-cell chronic lymphocytic leukemia patients previously treated with chlorambucil as up-front therapy and a CHOP-like regimen as second line therapy.
    Liso V; Molica S; Capalbo S; Pogliani E; Battista C; Broccia G; Montillo M; Cuneo A; Leoni P; Specchia G; Castoldi G
    Haematologica; 2001 Nov; 86(11):1165-71. PubMed ID: 11694402
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 2-Chlorodeoxyadenosine treatment in non-Hodgkin's lymphoma and B-cell chronic lymphocytic leukemia resistant to conventional chemotherapy: results of a multicentric experience. International Society for Chemo-Immunotherapy.
    Brugiatelli M; Holowiecka B; Dmoszynska A; Krieger O; Planinc-Peraica A; Labar B; Callea V; Morabito F; Jaksic B; Holowiecki J; Lutz D
    Ann Hematol; 1996 Aug; 73(2):79-84. PubMed ID: 8774616
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: report of a prospective, multicenter, randomized trial of the Polish Adult Leukemia Group (PALG CLL2).
    Robak T; Blonski JZ; Gora-Tybor J; Jamroziak K; Dwilewicz-Trojaczek J; Tomaszewska A; Konopka L; Ceglarek B; Dmoszynska A; Kowal M; Kloczko J; Stella-Holowiecka B; Sulek K; Calbecka M; Zawilska K; Kuliczkowski K; Skotnicki AB; Warzocha K; Kasznicki M;
    Blood; 2006 Jul; 108(2):473-9. PubMed ID: 16551966
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term survival following cladribine (2-chlorodeoxyadenosine) therapy in previously treated patients with chronic lymphocytic leukemia.
    Juliusson G; Liliemark J
    Ann Oncol; 1996 Apr; 7(4):373-9. PubMed ID: 8805929
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients.
    Leporrier M; Chevret S; Cazin B; Boudjerra N; Feugier P; Desablens B; Rapp MJ; Jaubert J; Autrand C; Divine M; Dreyfus B; Maloum K; Travade P; Dighiero G; Binet JL; Chastang C;
    Blood; 2001 Oct; 98(8):2319-25. PubMed ID: 11588025
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Does intensive treatment with high dose chlorambucil and prednisone as first line and cladribine as second line influence the survival of the patients with chronic lymphocytic leukemia?
    Robak T; Błoński JZ; Kasznicki M
    Leuk Lymphoma; 2001 May; 41(5-6):545-57. PubMed ID: 11378572
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 2-Chlorodeoxyadenosine therapy in advanced chronic lymphocytic leukaemia.
    Delannoy A; Ferrant A; Martiat P; Montfort L; Doyen C; Sokal G; Michaux JL
    Nouv Rev Fr Hematol (1978); 1994 Aug; 36(4):311-5. PubMed ID: 7971251
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rituximab plus cladribine with or without cyclophosphamide in patients with relapsed or refractory chronic lymphocytic leukemia.
    Robak T; Smolewski P; Cebula B; Grzybowska-Izydorczyk O; Błoński JZ
    Eur J Haematol; 2007 Aug; 79(2):107-13. PubMed ID: 17635235
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Weekly administration of 2-chlorodeoxyadenosine in patients with hairy-cell leukemia is effective and reduces infectious complications.
    Lauria F; Bocchia M; Marotta G; Raspadori D; Zinzani PL; Rondelli D
    Haematologica; 1999 Jan; 84(1):22-5. PubMed ID: 10091389
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High complete remission rate from 2-chloro-2'-deoxyadenosine in previously treated patients with B-cell chronic lymphocytic leukemia: response predicted by rapid decrease of blood lymphocyte count.
    Juliusson G; Liliemark J
    J Clin Oncol; 1993 Apr; 11(4):679-89. PubMed ID: 8097528
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of a 2-hour infusion of 2-chlorodeoxyadenosine in the treatment of refractory or previously untreated Waldenström's macroglobulinemia.
    Hellmann A; Lewandowski K; Zaucha JM; Bieniaszewska M; Hałaburda K; Robak T
    Eur J Haematol; 1999 Jul; 63(1):35-41. PubMed ID: 10414453
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cladribine in the treatment of relapsed or refractory chronic lymphocytic leukemia.
    Tallman MS; Hakimian D; Zanzig C; Hogan DK; Rademaker A; Rose E; Variakojis D
    J Clin Oncol; 1995 Apr; 13(4):983-8. PubMed ID: 7707127
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease.
    Montoto S; Camós M; López-Guillermo A; Bosch F; Cervantes F; Blandé J; Esteve J; Cobo F; Nomdedeu B; Campo E; Montserrat E
    Cancer; 2000 May; 88(9):2142-8. PubMed ID: 10813727
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia.
    O'Brien SM; Kantarjian HM; Cortes J; Beran M; Koller CA; Giles FJ; Lerner S; Keating M
    J Clin Oncol; 2001 Mar; 19(5):1414-20. PubMed ID: 11230486
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL.
    Johnson S; Smith AG; Löffler H; Osby E; Juliusson G; Emmerich B; Wyld PJ; Hiddemann W
    Lancet; 1996 May; 347(9013):1432-8. PubMed ID: 8676625
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A phase II study of sequential combination chemotherapy with cyclophosphamide, prednisone, and 2-chlorodeoxyadenosine in previously untreated patients with chronic lymphocytic leukemia.
    Tefferi A; Li CY; Reeder CB; Geyer SM; Allmer C; Levitt R; Michalak JC; Addo F; Krook JE; Witzig TE; Schaefer PL; Mailliard JA
    Leukemia; 2001 Aug; 15(8):1171-5. PubMed ID: 11480558
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.